Fig 1: DNMT3B3 overexpression validated in advanced stages of high-grade serous ovarian carcinoma (HGSOC). DNMT3B3 isoform overexpression in two arrays of cDNA rapid cDNA panels: II and III, of ovarian carcinoma (TissueScan Ovarian Cancer cDNA arrays II and III) (OriGene Technologies, Rockville MD) (cat. no. HORT102, and 103) (n = 82). Non-advanced HGSOC (n = 23: mucinous, low-grade serous ovarian carcinoma, endometrioid, carcinoma clear cells, and stages I–II of HGSOC) versus advanced HGSOC (n = 59: stages III–IV of HGSOC). Assays were normalized with GAPDH expression in each case and ten controls of the normal ovary. Mann–Whitney U test was used.
Fig 2: Survival analysis among patients with OCCC associated with SLIT2 mRNA expression. (A) Lower expression levels of SLIT2 were observed in 4/5 of the cDNA T samples compared with the N samples from tissue array panels (cat. nos. HORT102 and HORT104; OriGene Technologies, Inc.). (B) Low SLIT2 expression was associated with poor PFS in patients with OCCC based on the data of the GSE8841 and GSE65986 projects. SLIT2, slit guidance ligand 2; OCCC, ovarian clear cell carcinoma; N, normal; T, tumor; PFS, progression-free survival.
Supplier Page from OriGene Technologies for TissueScan, Ovarian Cancer cDNA Array II